Lexapro Tapering Guide
escitalopram
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.
Overview
Escitalopram is the therapeutically active S-enantiomer of citalopram, an SSRI used for the treatment of major depressive disorder and generalized anxiety disorder. It is considered one of the most selective SSRIs available.
5mg, 10mg, 20mg
Tablets: 5mg, 10mg, 20mg; Oral solution: 1mg/mL
Category C (risk cannot be ruled out)
Mechanism of Action
Selective serotonin reuptake inhibitor (SSRI) that binds with high affinity to the serotonin transporter (SERT), blocking reuptake of serotonin into the presynaptic neuron and increasing serotonergic neurotransmission.
Taper Notes
Hyperbolic taper recommended. Reductions of ~10% of the previous dose, slowing further below 5 mg. Liquid formulation (1 mg/mL) supports precise sub-tablet dosing.
Maudsley Deprescribing Guidance
Apply proportional (hyperbolic) reductions: smaller absolute decrements as the dose decreases. The 2.5 mg → 0 step is the highest-risk transition; liquid escitalopram enables dose increments below 2.5 mg.
Tapering Protocol
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Initial reductions | ~4 weeks | Larger absolute steps are typically tolerated at higher receptor occupancy. Reduce by ~25% of current dose every 2–4 weeks at this stage. |
| Middle reductions | 4-6 weeks | Transition to ~10% proportional reductions. Liquid formulation aids precision once tablet halves become inadequate. |
| Final reductions | 8-12 weeks | Below 5 mg, SERT occupancy curves steeply; use liquid for sub-mg increments and extend hold periods to 4+ weeks if symptoms emerge. |
Withdrawal Timeline
1-3 days after dose reduction
4-7 days
2-4 weeks for most symptoms
Brain zaps and emotional blunting may persist 1-3 months in some cases
Clinical Pearls
Practical considerations for clinicians supervising Lexapro tapers.
- 1Liquid escitalopram (1 mg/mL) enables fine titration below 5 mg, where hyperbolic curves require sub-tablet doses. Compounded suspensions are an alternative when the proprietary liquid is unavailable.
- 2Brain zaps (paresthesias) are the most reported discontinuation symptom and tend to intensify in late-stage reductions; they are not predictive of long-term harm.
- 3If the patient develops a withdrawal wave, hold the current dose until symptoms stabilize for 2–4 weeks before resuming reductions; do not push through.
- 4The terminal portion of the taper is disproportionately demanding due to non-linear receptor occupancy. Plan extended timelines and patient check-ins below 2.5 mg.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- MAOIs — contraindicated (risk of serotonin syndrome)
- CYP2C19 inhibitors (e.g., omeprazole) may increase escitalopram levels
- Serotonergic drugs (triptans, tramadol, St. John's Wort) increase serotonin syndrome risk
Food Interactions
- Grapefruit juice may increase levels via CYP3A4 inhibition
- No significant food effect on absorption
Contraindications
- MAOIs within 14 days
- Pimozide
- Known hypersensitivity to escitalopram or citalopram
Toxicity
Serotonin syndrome at high doses or in combination with serotonergic agents. QT prolongation rare but dose-dependent.
External References
Pharmacokinetics
ADME Profile
Rapidly absorbed after oral administration, Tmax ~5 hours, bioavailability ~80%, unaffected by food.
~12 L/kg
Hepatic via CYP3A4 and CYP2C19 to S-demethylcitalopram (S-DCT) and S-didemethylcitalopram (S-DDCT), both with minimal pharmacological activity.
Renal (~8% excreted unchanged) and hepatic metabolism.
~56%
~600 mL/min (oral clearance)
Build Lexapro taper plans in minutes
TaperMeds turns these protocols into prescriber-ready taper schedules with hyperbolic dose curves, symptom tracking, and patient handouts — for the clinicians supervising the taper.
Try TaperMeds